About
Rosetta Genomics develops and commercializes a range of microRNA-based and other molecular diagnostics. The companys integrative research platform, combining bioinformatics and laboratory processes, has led to the discovery of hundreds of biologically validated novel human microRNAs. Rosetta Genomics is advancing and developing multiple diagnostic programs for cancer and various other indications to enable accurate diagnosis and prognosis and to improve patient care management worldwide. The RosettaGX platform of tests uses blended technology platforms (e.g. microRNA, FISH, and next-generation sequencing) along with proprietary scientific approaches for each tumor type in its offering. It chooses the most clinically informative and relevant testing based on an ongoing and thorough review of scientific literature and an internal medical review process.